Cocrystal Pharma, Inc. (COCP)
$0.4205
Rating:
Recommendation:
Buy
| Symbol | COCP |
|---|---|
| Price | $0.4205 |
| Beta | 0.800 |
| Volume Avg. | 0.26M |
| Market Cap | 40.986M |
| Shares () | - |
| 52 Week Range | 0.37-1.49 |
| 1y Target Est | - |
| DCF Unlevered | COCP DCF -> | |
|---|---|---|
| DCF Levered | COCP LDCF -> | |
| ROE | -15.11% | Sell |
| ROA | -15.89% | Sell |
| Operating Margin | - | |
| Debt / Equity | 2.44% | Neutral |
| P/E | - | |
| P/B | 0.56 | Buy |
Latest COCP news
About
Download (Excel)Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.